BMO cuts Doximity stock price target on macro headwinds, AI costs

BMO Capital cut Doximity’s price target to $20 from $25 and kept a Market Perform rating, citing persistent macro headwinds and elevated AI investment costs. Although Q4 revenue of $145.4 million and adjusted EBITDA of $65.8 million both beat estimates, fiscal 2027 guidance of $664 million-$676 million revenue and 3%-$5% growth fell well below the Street’s $699 million expectation. The stock has already fallen 61% over the past year and now trades near its 52-week low of $20.55.

Analysis

The market is likely extrapolating a one-year narrative reset into a multi-year structural impairment, but the more important signal is that Doximity is choosing to spend through a weak macro backdrop rather than defend near-term margin optics. That usually hurts in the first two quarters because sell-side models lag the step-up in AI-related opex and marketing, but it can set up a cleaner second-half re-rate if monetization converts faster than expected. The current setup is less about a broken product and more about a credibility gap between management’s investment cadence and the Street’s willingness to underwrite that spend.

Second-order, the pressure likely shifts to adjacent digital health and SaaS names that are still trading on “AI optionality” without near-term proof points. If DOCS is being repriced for insufficient visibility on commercialization, investors may demand a higher bar for anything pitching AI as a growth lever rather than a margin tool. That creates a relative-value headwind for higher-multiple healthcare software names with similar ad/budget exposure and weak budget cycles, while more defensible platform plays with clearer ROI can outperform.

The near-term catalyst path is asymmetric: another guide-down or chatter about elongated sales cycles would likely trigger a further de-rating over the next 1-2 quarters, especially if analyst estimate revisions keep rolling lower. The main reversal would be evidence that AI features materially lift engagement or CPM-style monetization by the next earnings cycle, or that management’s spending peak is contained to a single fiscal year. In that sense, the stock is cheap only if the company can prove that this is an investment trough, not a margin plateau.

Contrarianly, the selloff may already be pricing in a prolonged deterioration in growth that is not yet visible in the actual operating data. If revenue still grows in the mid-single digits and EBITDA remains high-quality, the market may be over-penalizing a forward guide that embeds temporary macro weakness plus a front-loaded AI cost curve. The risk to being too bearish is that any stabilization in healthcare advertising budgets could drive a violent mean reversion because positioning has likely already moved heavily defensive.

Key Decisions for Investors

• Short DOCS into the next earnings window if the stock rallies toward the high-$20s; risk/reward favors fading strength until management shows AI monetization translating into acceleration, with downside back toward the low-$20s if guidance credibility remains weak.
• For a tactical hedge, buy DOCS put spreads 1-3 months out around the next print; structure for a 2:1 or better payoff if another revision lower or margin compression hits, while capping premium burn if the name stabilizes.
• Pair trade: long a higher-quality digital health / healthcare software name with clearer near-term monetization, short DOCS, to isolate the market’s premium for execution visibility over AI narrative. Hold for 1-2 quarters and exit on any evidence of budget stabilization.
• If you want a contrarian long, wait for post-earnings washout and buy only if management demonstrates AI revenue contribution or a moderation in expense growth; target a 6-12 month horizon with a tight stop below the prior low.
• Reduce exposure to other AI-story software names with weak current monetization if DOCS continues to de-rate; the read-through is that the market is no longer paying for optionality without proof, especially in slower-growth vertical software.